Open

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Dose-Range Finding Study of ORKA-001 in Participants with Moderate -to-Severe Plaque Psoriasis

The purpose of this study is to evaluate efficacy of the an investigational medication compared to placebo in participant with moderate-to-severe plaque psoriasis.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will meet with a member of the study team and fill out questionnaires. The study also involves collecting vital signs, blood draws, urine testing, ECGs, physical exams willingness to provide medical history and use of medications, use of birth control method if applicable, and willingness to take the study medication as directed.

Incentives

Information provided upon request

In-person visits:
21

Phone or online visits:
3

Total length of participation:
154 weeks

Looking for Specific Volunteers

Able to participate:

you are 18 years or older
you have a diagnosis of Plaque Psoriasis
Willing to give informed consent
Body mass index (BMI) ≥ 18.5 kg/m2

Not eligible if:

have nonplaque forms of psoriasis
Received immunosuppressive therapy in the past 5 years

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

UNC Dermatology and Skin Cancer Center at Southern Village
410 Market St Ste 400, Chapel Hill, NC 27516, USA

Additional Study Information

Principal Investigator

Laura Ferris
Dermatology-Research

Study Type

Clinical or Medical
Interventional

Study Topics

Skin, Hair, and Nails

IRB Number

25-2697

ClinicalTrials.gov

not yet available

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.